AZTA logo

Azenta, Inc. Stock Price

NasdaqGS:AZTA Community·US$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

AZTA Share Price Performance

US$33.38
2.99 (9.84%)
US$27.80
Fair Value
US$33.38
2.99 (9.84%)
20.1% overvalued intrinsic discount
US$27.80
Fair Value
Price US$33.38
AnalystConsensusTarget US$27.80
AnalystLowTarget US$20.00
AnalystHighTarget US$33.00

AZTA Community Narratives

·
Fair Value US$27.8 20.1% overvalued intrinsic discount

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$20 66.9% overvalued intrinsic discount

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$33 1.2% overvalued intrinsic discount

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

AZTA logo

AZTA: Index Additions And Refined Assumptions Will Support Gradual Sentiment Recovery

Fair Value: US$27.8 20.1% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AZTA logo

AZTA: Portfolio Refocus And Index Additions Will Support Future Upside Potential

Fair Value: US$33 1.2% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AZTA logo

AZTA: Future P/E Compression And Impairment Charges Will Pressure Returns

Fair Value: US$20 66.9% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

0 Risks
2 Rewards

Azenta, Inc. Key Details

US$613.8m

Revenue

US$343.4m

Cost of Revenue

US$270.4m

Gross Profit

US$382.5m

Other Expenses

-US$112.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-2.56
44.05%
-18.26%
0%
View Full Analysis

About AZTA

Founded
1978
Employees
2900
CEO
John P. Marotta
WebsiteView website
www.azenta.com

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Recent AZTA News & Updates

Seeking Alpha 12h

Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue

Summary AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out. There is reason to suspect the rally could undergo a reversal, which is why I am neutral on AZTA with a hold rating. Read the full article on Seeking Alpha

Recent updates

No updates